Epigral Q4 Revenue Hits Record ₹736 Crore, Up 22%

Epigral reported Q4FY26 record revenue of ₹736 crore, up 22% QoQ, with EBITDA surging 64% to ₹169 crore.
FY26 revenue declined 1% to ₹2,542 crore, while PAT was ₹333 crore, including an ₹81 crore deferred tax benefit.
The board proposed a final dividend of ₹5 per share and spent ₹394 crore on capex for CPVC and ECH expansion.
Key expansion projects for CPVC and Epichlorohydrin are on schedule for H1FY27 commissioning, targeting domestic demand growth.